New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy

The landmark DAPA-CKD trial showed that dapagliflozin slows CKD progression regardless of diabetes status. Now a prespecified analysis suggests it also works for CKD patients with an IgA etiology.Medscape Medical News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Nephrology News Source Type: news